Psoriasis
Disease State Hub
Featured
04/16/2026
March 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
04/16/2026
03/19/2026
Anthony Calabro, MA
The FDA has approved icotrokinra, an oral interleukin-23 receptor antagonist, for patients aged 12 years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or...
03/19/2026
11/27/2025
Joel M. Gelfand, MD, MSCE
In a recent presentation at Practical Updates in Primary Care, Joel M. Gelfand, MD, provided an overview of psoriasis care for primary care providers alongside co-presenter Annie Truss, MD. In this...
11/27/2025
Interactive Features
09/02/2025
Kate Young
A recent study found that interclass biologic switching in psoriasis demonstrated faster short-term and more stable long-term effectiveness. However, switching was associated with an increased risk of...
09/02/2025
02/11/2025
Miranda Manier, BA
A recent study explores the long-term safety and efficacy of deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate-to-severe plaque psoriasis. Do you know the role TYK2 plays in...
02/11/2025
01/27/2025
Miranda Manier, BA
A recent study investigates the use of apremilast for pediatric patients with moderate-to-severe plaque psoriasis. Can you identify one of the key benefits of this treatment option for children? Take our...
01/27/2025
09/10/2024
When managing patients with psoriatic arthritis who do not respond to tumor necrosis factor inhibitors, clinicians must consider several factors before changing their treatment. Think you know what they...
09/10/2024
05/21/2023
According to the National Psoriasis Foundation Medical Board, what diet is strongly recommended for patients with psoriasis with overweight and obesity?
05/21/2023
Clinical Insights
11/27/2025
Joel M. Gelfand, MD, MSCE
In a recent presentation at Practical Updates in Primary Care, Joel M. Gelfand, MD, provided an overview of psoriasis care for primary care providers alongside co-presenter Annie Truss, MD. In this...
11/27/2025
11/24/2025
Douglas DiRuggiero, DMSc, MHS, PA-C
Veteran dermatology Physician Assistant Douglas DiRuggiero, PA-C, DMSc, shares practical insights on how he incorporates ZORYVE® (roflumilast) into the treatment of atopic dermatitis, seborrheic...
11/24/2025
11/12/2025
Douglas DiRuggiero, DMSc, MHS, PA-C
In this episode of Ask the Experts, dermatology Physician Assistant Douglas DiRuggiero, PA-C, DMSc, shares what's unique about the formulations of ZORYVE® (roflumilast). Mr. DiRuggiero discusses how...
11/12/2025
04/17/2025
Ana Ormaza Vera, MD
In this interview, Ana Ormaza Vera, MD, discusses findings from a study she presented at the American College of Cardiology’s 74th Annual Scientific Session & Expo on March 29, 2025, in Chicago. She...
04/17/2025
04/03/2025
Loretta Fiorillo, MD, FRCPC
Loretta Fiorillo, MD, FRCPC, Director of Pediatrics and Dermatology at the University of Alberta, discusses findings from a study on apremilast for pediatric psoriasis.
04/03/2025
